|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 117.98 CHF | +1.85% |
|
+0.14% | +7.65% |
| 06-05 | Flerie Affirms Confidence in Xspray Pharma's Cancer Drug After US FDA Letter | MT |
| 06-05 | Xspray Pharma Gets US FDA Complete Response Letter for Cancer Drug Application | MT |
| Capitalization | 272B 235B 216B 203B 378B 25,900B 384B 2,567B 999B 12,525B 1,021B 998B 43,558B | P/E ratio 2026 * |
20.6x | P/E ratio 2027 * | 17.6x |
|---|---|---|---|---|---|
| Enterprise value | 304B 263B 242B 227B 423B 28,979B 430B 2,872B 1,118B 14,015B 1,142B 1,117B 48,736B | EV / Sales 2026 * |
5.32x | EV / Sales 2027 * | 4.95x |
| Free-Float |
91.66% | Yield 2026 * |
3.06% | Yield 2027 * | 3.14% |
Last Transcript: Novartis AG
Trading Novartis AG
| 1 day | +1.85% | ||
| 1 week | +0.14% | ||
| Current month | +0.14% | ||
| 1 month | +2.02% | ||
| 3 months | -4.28% | ||
| 6 months | +10.18% | ||
| Current year | +7.65% |
| 1 week | 111.48 |  | 118 |
| 1 month | 111.48 | | 120.26 |
| Current year | 107.68 | | 131 |
| 1 year | 91.2 | | 131 |
| 3 years | 81.1 | | 131 |
| 5 years | 72.84 | | 131 |
| 10 years | 65.09 | | 131 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 01/02/2018 | |
Mukul Mehta
DFI | Director of Finance/CFO | - | 16/03/2026 |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 64 | 16/05/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Nancy Andrews
BRD | Director/Board Member | 68 | 01/01/2015 |
| Director/Board Member | 69 | 01/01/2016 | |
Ton Büchner
BRD | Director/Board Member | 61 | 01/01/2016 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 05-18 | Sell | -5,200 | 0.0003% | |||
| 05-04 | Sell | 6,800 | 0.0003% | |||
| 02-17 | Sell | 30,743 | 0.0015% |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.85% | +0.14% | +21.53% | +30.34% | 272B | |
| +0.55% | +2.39% | +46.96% | +155.36% | 1,009B | |
| +2.02% | +3.30% | +50.15% | +47.16% | 560B | |
| +1.02% | +4.37% | +19.70% | +67.78% | 401B | |
| +0.77% | -0.67% | +21.96% | +11.96% | 328B | |
| +2.24% | +0.41% | +28.53% | +17.12% | 288B | |
| +4.43% | -3.11% | -42.11% | -49.56% | 194B | |
| +1.15% | +3.80% | +20.41% | +58.02% | 189B | |
| -0.02% | -3.92% | +14.85% | +69.50% | 160B | |
| +1.36% | -0.53% | +11.52% | -32.13% | 148B | |
| Average | +1.54% | +0.97% | +19.35% | +37.55% | 355B | |
| Weighted average by Cap. | +1.34% | +1.84% | +29.41% | +66.24% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 57.12B 49.47B 45.39B 42.71B 79.54B 5,444B 80.78B 540B 210B 2,633B 214B 210B 9,155B | 60.58B 52.46B 48.13B 45.29B 84.35B 5,773B 85.67B 572B 223B 2,792B 227B 223B 9,708B |
| Net income | 14.15B 12.25B 11.24B 10.58B 19.7B 1,348B 20.01B 134B 52.01B 652B 53.13B 51.97B 2,268B | 15.69B 13.58B 12.46B 11.73B 21.84B 1,495B 22.18B 148B 57.66B 723B 58.89B 57.61B 2,514B |
| Net Debt | 32.31B 27.98B 25.68B 24.16B 44.99B 3,079B 45.69B 305B 119B 1,489B 121B 119B 5,178B | 28.33B 24.53B 22.51B 21.18B 39.45B 2,700B 40.07B 268B 104B 1,306B 106B 104B 4,540B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/06/26 | 117.98 CHF | +1.85% | 3,018,356 |
| 04/06/26 | 115.84 CHF | +2.04% | 2,867,918 |
| 03/06/26 | 113.52 CHF | +0.46% | 2,862,812 |
| 02/06/26 | 113.00 CHF | -0.79% | 2,699,639 |
| 01/06/26 | 113.90 CHF | -3.33% | 2,973,046 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition